Effects of Immunotherapy Clinical Trial
Official title:
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients: Correlation With Disease Severity and Their Role as Biomarkers for Efficacy of Sublingual Immunotherapy
Verified date | December 2022 |
Source | Zagazig University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is: - to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for efficacy of sublingual immunotherapy. - also to find if high sensitivity CRP can be an easy non-expensive test for diagnosis and follow up of allergic rhinitis patients.
Status | Completed |
Enrollment | 64 |
Est. completion date | October 10, 2022 |
Est. primary completion date | September 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Patient consent. 2. Patients between 6-60 years old suffering from allergic rhinitis clinically. 3. Positive skin prick test Exclusion Criteria: - 1- Chronic inflammatory condition as COPD, tuberculosis, aspergillosis and chronic hepatitis. 2- Other allergic diseases as bronchial asthma, allergic conjunctivitis and chronic urticaria 3- Those undergoing chronic treatment with systemic steroids or B- blockers 4- Systemic immunological disorders as systemic lupus erythematous, rheumatoid arthritis and systemic sclerosis. 5- Malignancy |
Country | Name | City | State |
---|---|---|---|
Egypt | Fatma Zohry Kamel Khater | Zagazig |
Lead Sponsor | Collaborator |
---|---|
Zagazig University |
Egypt,
Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37. doi: 10.1038/s41580-018-0045-7. — View Citation
Hosseini SA, Zilaee M, Shoushtari MH, Ghasemi Dehcheshmeh M. An evaluation of the effect of saffron supplementation on the antibody titer to heat-shock protein (HSP) 70, hsCRP and spirometry test in patients with mild and moderate persistent allergic asthma: A triple-blind, randomized placebo-controlled trial. Respir Med. 2018 Dec;145:28-34. doi: 10.1016/j.rmed.2018.10.016. Epub 2018 Oct 19. — View Citation
Hou B, Murata M, Said AS, Sakaida H, Masuda S, Takahashi T, Zhang Z, Takeuchi K. Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. Allergy Rhinol (Providence). 2015 Jan;6(1):33-8. doi: 10.2500/ar.2015.6.0107. Epub 2015 Feb 11. — View Citation
Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep. 2014 Nov;14(11):473. doi: 10.1007/s11882-014-0473-1. — View Citation
Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007 Sep;120(3 Suppl):S25-85. doi: 10.1016/j.jaci.2007.06.019. No abstract available. Erratum In: J Allergy Clin Immunol. 2009 Jun;123(6):1421. J Allergy Clin Immunol.2008 Oct;122(4):842. J Allergy Clin Immunol. 2008 Oct;122(4):842. — View Citation
Jutel M, Kosowska A, Smolinska S. Allergen Immunotherapy: Past, Present, and Future. Allergy Asthma Immunol Res. 2016 May;8(3):191-7. doi: 10.4168/aair.2016.8.3.191. — View Citation
Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 2007 Jan 1;178(1):496-502. doi: 10.4049/jimmunol.178.1.496. — View Citation
Luo X, Hong H, Tang J, Wu X, Lin Z, Ma R, Fan Y, Xu G, Liu D, Li H. Increased Expression of miR-146a in Children With Allergic Rhinitis After Allergen-Specific Immunotherapy. Allergy Asthma Immunol Res. 2016 Mar;8(2):132-40. doi: 10.4168/aair.2016.8.2.132. Epub 2015 Oct 22. — View Citation
Moustafa Y, El Nady HG, Saber MM, Dabbous OA, Kamel TB, Abel-Wahhab KG, Sallam SF, Zaki DA. Assessment of Allergic Rhinitis among Children after Low-Level Laser Therapy. Open Access Maced J Med Sci. 2019 Jun 30;7(12):1968-1973. doi: 10.3889/oamjms.2019.477. eCollection 2019 Jun 30. — View Citation
Panganiban RP, Lambert KA, Hsu MH, Laryea Z, Ishmael FT. Isolation and profiling of plasma microRNAs: Biomarkers for asthma and allergic rhinitis. Methods. 2019 Jan 1;152:48-54. doi: 10.1016/j.ymeth.2018.06.007. Epub 2018 Jun 12. — View Citation
Panganiban RP, Pinkerton MH, Maru SY, Jefferson SJ, Roff AN, Ishmael FT. Differential microRNA epression in asthma and the role of miR-1248 in regulation of IL-5. Am J Clin Exp Immunol. 2012 Nov 15;1(2):154-65. Print 2012. — View Citation
Platts-Mills TA. The allergy epidemics: 1870-2010. J Allergy Clin Immunol. 2015 Jul;136(1):3-13. doi: 10.1016/j.jaci.2015.03.048. — View Citation
Specjalski K, Jassem E. MicroRNAs: Potential Biomarkers and Targets of Therapy in Allergic Diseases? Arch Immunol Ther Exp (Warsz). 2019 Aug;67(4):213-223. doi: 10.1007/s00005-019-00547-4. Epub 2019 May 28. — View Citation
Zhao Y, Zhao Y, Zhang Y, Zhang L. HLA-II genes are associated with outcomes of specific immunotherapy for allergic rhinitis. Int Forum Allergy Rhinol. 2019 Nov;9(11):1311-1317. doi: 10.1002/alr.22384. Epub 2019 Jul 12. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MiRNA146a, microRNA 223 measurements | Effect of sublingual immunotherapy on the miRNA146, MicroRNA 223 on allergic rhinitis patients | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05098171 -
Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors
|
Early Phase 1 | |
Recruiting |
NCT05098184 -
Study on TIL for the Treatment of Advanced Melanoma
|
Early Phase 1 | |
Recruiting |
NCT05098197 -
Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers
|
Early Phase 1 | |
Completed |
NCT02169609 -
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
|
Phase 2 | |
Completed |
NCT01486498 -
Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy
|
N/A | |
Recruiting |
NCT05142475 -
Study on TIL for the Treatment of Advanced Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT05420922 -
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
|
||
Completed |
NCT03388866 -
Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis
|
Phase 4 | |
Completed |
NCT02164461 -
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
|
Phase 1 | |
Completed |
NCT02406183 -
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05468307 -
Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors
|
Early Phase 1 | |
Completed |
NCT01863108 -
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT03638375 -
TIL and Anti-PD1 in Metastatic Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT02765243 -
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
|
Phase 1 | |
Completed |
NCT01291381 -
Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children
|
N/A | |
Recruiting |
NCT01513109 -
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05087745 -
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
|
Early Phase 1 | |
Recruiting |
NCT05885048 -
Impact of Gonadotoxic Therapies on Fertility
|
||
Withdrawn |
NCT01437020 -
SCH708980 With and Without AmBisome for Visceral Leishmaniasis
|
Phase 1/Phase 2 |